2021
DOI: 10.3390/ijerph18020394
|View full text |Cite
|
Sign up to set email alerts
|

Cost of Venous Thromboembolic Disease in Patients with Lung Cancer: COSTECAT Study

Abstract: Background: Patients with lung cancer (LC) are at significantly higher risk of developing venous thromboembolism (VTE), which may lead to increased use of health resources and the cost of the disease management. The main aim of the study was to determine the cost of the management of VTE events in patients with LC treated with Low Molecular Weight Heparins (LMWH) in Spain. Methods: Costecat was an observational, ambispective pharmacoeconomic study. Patients with LC, with a first episode of VTE (symptomatic or … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1

Citation Types

0
3
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
5
1

Relationship

0
6

Authors

Journals

citations
Cited by 7 publications
(4 citation statements)
references
References 23 publications
0
3
0
Order By: Relevance
“…Nearly half of real-world patients receiving chemotherapy for metastatic NSCLC are hospitalized during their therapy [118]. Out of 570,304 LC hospitalizations, 20,672 (3.6%) had a clinically relevant diagnosis of CAT resulting in significantly longer length of stay, higher mortality, increased costs and increased risk for moderate to severe disability upon discharge [119]. Hospitalized patients with active LC and acute medical illness should be offered thromboprophylaxis.…”
Section: Prophylaxis In the Medical Settingmentioning
confidence: 99%
“…Nearly half of real-world patients receiving chemotherapy for metastatic NSCLC are hospitalized during their therapy [118]. Out of 570,304 LC hospitalizations, 20,672 (3.6%) had a clinically relevant diagnosis of CAT resulting in significantly longer length of stay, higher mortality, increased costs and increased risk for moderate to severe disability upon discharge [119]. Hospitalized patients with active LC and acute medical illness should be offered thromboprophylaxis.…”
Section: Prophylaxis In the Medical Settingmentioning
confidence: 99%
“…Ironically, this trend affects decision making in the oncologic population, inasmuch as there is currently no validated method of classification that facilitates choosing episodes with a good prognosis for ambulatory management [ 3 , 8 , 16 , 17 ]. Inarguably, averting hospitalizations would lower costs, avoid iatrogenesis, and improve quality of life [ 18 ]. Although there are some limited data and guidelines suggesting that outpatient management of cancer-related PE is feasible, high-quality prospective data supporting this approach is still lacking [ 3 , 19 21 ].…”
Section: Introductionmentioning
confidence: 99%
“…Ironically, this trend affects decision making in the oncologic population, inasmuch as there is currently no validated method of classification that facilitates choosing episodes with a good prognosis for ambulatory management [2,1012]. Inarguably, averting hospitalizations would lower costs, avoid iatrogenesis, and improve quality of life [13]. Nonetheless, outpatient management of cancer-related PE is not based on quality evidence, and there is a glaring dearth of prospective data [14].…”
Section: Introductionmentioning
confidence: 99%